To explore cross-cancer predictive potential for targeted therapeutics, we applied CONCORD to two targeted therapeutic agents: Erlotinib (an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor) and Vemurafenib (a B-RAF inhibitor). This evidence concerns the gene EGFR and cancer.